Healthtech Startups
17,197 companies tagged Healthtech, with their investors and founders.
Marius Pharmaceuticals develops therapies for hormonal and metabolic health, with a focus on treating testosterone deficiency and hypogonadism in men and women. The company works in the pharmaceutical and biotech space, offering research-based treatments aimed at improving hormone balance and metabolic function.
0 investors
0 investors
0 investors
MarvelBiome is a clinical-stage biotechnology company developing Live Biotherapeutic Products through engineered bacterial consortia designed to treat disease-specific conditions. The company focuses on microbiome-based treatments for patients.
0 investors
0 investors
0 investors
0 investors
Mati Therapeutics develops a non-invasive sustained drug delivery platform, the Evolute Punctal Plug Delivery System, for treating ocular diseases such as glaucoma. The device delivers medication over an extended period, removing the need for patients to administer eye drops.
0 investors
0 investors
0 investors
0 investors
Maverix Oncology develops conditionally activated small molecule therapeutics for cancer treatment, led by a team of oncologists and cancer scientists with experience in drug discovery and development.
0 investors
0 investors
0 investors
0 investors
MAXONA Pharmaceuticals develops non-opioid pain treatment options for the U.S. market. The company is focused on expanding therapeutic alternatives in pain management.
0 investors
Maxymune is a pharmaceutical company developing treatments for immunological diseases, including a small-molecule LAT1 inhibitor program targeting overactive T-cells in autoimmune conditions and an improved formulation of mycophenolic acid intended to reduce gastrointestinal side effects. Its work spans drug discovery and formulation of immunosuppressive therapies for patients with immunological disorders.
0 investors
0 investors
0 investors
0 investors
0 investors
MBQ Pharma develops precision therapeutics that target Rac and CDC42 GTPases for cancer, autoimmune, and fibrotic diseases, with a lead compound (MBQ-167) aimed at preventing and removing metastases. Its lead candidate is in a Phase 1 study, based on IP licensed from the University of Puerto Rico.
0 investors
0 investors
0 investors